Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time, Bone Marrow Transplant, vol.36, issue.9, pp.757-769, 2005. ,
Reduced mortality after allogeneic hematopoietic-cell transplantation, N Engl J Med, vol.363, issue.22, pp.2091-2101, 2010. ,
Advances in prevention and treatment of hepatic disorders following hematopoietic cell transplantation, Best Pract Res Clin Haematol. juin, vol.19, issue.2, pp.341-52, 2006. ,
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients, Blood. 1 janv, vol.103, issue.1, pp.78-84, 2004. ,
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome, Bone Marrow Transplant, vol.44, issue.7, pp.441-447, 2009. ,
Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation, Hepatology. févr, vol.41, issue.2, pp.345-52, 2005. ,
Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with ,
, Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant, vol.18, issue.10, pp.1589-99, 2012.
Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation, Eur J Gastroenterol Hepatol, vol.16, issue.12, pp.1347-1354, 2004. ,
,
, Chronic cholestasis in patients after allogeneic bone marrow transplantation: several diseases are often associated, Bone Marrow Transplant. août, vol.16, issue.2, pp.261-266, 1995.
Cholestasis after hematopoietic cell transplantation, Clin Liver Dis. août, vol.3, issue.3, pp.651-68, 1999. ,
Imaging Evaluation of Pulmonary and Abdominal Complications Following Hematopoietic Stem Cell Transplantation1 ,
, RadioGraphics. mars, vol.25, issue.2, pp.305-322, 2005.
Transjugular liver biopsy in BMT, Bone Marrow Transplant. janv, vol.11, issue.1, pp.21-27, 1993. ,
Activité nationale de greffe de CSH, 2016. ,
Modification of acute irradiation injury in mice and guinea-pigs by bone marrow injections, Radiology. juin, vol.58, issue.6, pp.863-77, 1952. ,
The restoration of marrow function after lethal irradiation in man: a review, Transplant Bull. oct, vol.6, pp.407-416, 1959. ,
,
, Rev Fr Etud Clin Biol. mars, vol.4, issue.3, pp.226-264, 1959.
, Trial
, Rev Fr Etud Clin Biol. sept, vol.4, pp.675-704, 1959.
,
, Successful allogenic bone marrow transplantation in man: chimerism, induced specific tolerance and possible anti-leukemic effects, Blood, vol.25, issue.2, pp.179-196, 1965.
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation, Blood, vol.49, issue.4, pp.511-533, 1977. ,
Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome, The Lancet, vol.292, issue.7583, pp.1364-1366, 1968. ,
Immunological reconstitution of sex-linked lymphopenic immunological deficiency, Lancet Lond Engl. 28 déc, vol.2, issue.7583, pp.1366-1375, 1968. ,
EMBT Handbook Haematopoietic Stem Cell transplantation. 6 e éd. Genoa: Forum f service editore, vol.683, 2012. ,
Haematopoietic cell transplantation as immunotherapy, NCI Dictionary of Cancer Terms, vol.411, 2001. ,
Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update, Blood, vol.115, pp.3861-3868, 2010. ,
Background to hematopoietic practice in Europe, Bone Marrow Transplant. août, vol.50, issue.8, pp.1037-56, 2015. ,
,
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel ,
, Haematologica. 1 mai, vol.99, issue.5, pp.811-831, 2014.
Update of hematopoietic cell transplantation for sickle cell disease, Curr Opin Hematol. mai, vol.22, issue.3, pp.227-260, 2015. ,
How I treat severe combined immunodeficiency, Blood, vol.122, issue.23, pp.3749-3758, 2013. ,
Wiskott-Aldrich Syndrome: Diagnosis, Clinical and Laboratory Manifestations, and Treatment, Biol Blood Marrow Transplant. janv, vol.15, issue.1, pp.84-90, 2009. ,
,
Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors, Blood, vol.90, issue.12, pp.4743-4748, 1997. ,
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, Bone Marrow Transplant. févr, vol.45, issue.2, pp.219-253, 2009. ,
Transplantation for bone marrow failure: current issues, Hematol Am Soc Hematol Educ Program. 2 déc, vol.2016, issue.1, pp.90-98, 2016. ,
Hematopoietic stem cell transplantation for acute myeloid leukemia: A review, Hematol Oncol Stem Cell Ther. déc, vol.10, issue.4, pp.245-51, 2017. ,
Treatment of relapsed/refractory acute myeloid leukaemia in adults, Br J Haematol, issue.9, 2018. ,
,
How I treat acute myeloid leukemia, Blood, vol.116, issue.17, pp.3147-56, 2010. ,
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet, J Clin Oncol. 10 déc, vol.27, issue.35, pp.6041-51, 2009. ,
,
, European LeukemiaNet recommendations for the management of chronic myeloid leukemia, Blood. 8 août, vol.122, issue.6, pp.872-84, 2013.
A review of the European LeukemiaNet recommendations for the management of CML, Ann Hematol. avr, vol.94, issue.S2, pp.141-148, 2015. ,
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion, Biol Blood Marrow Transplant, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02143674
,
,
, Use of hematopoietic cell transplantation for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia, Blood, 2017.
Allogeneic Stem Cell Transplantation in Myelofibrosis ,
, Biol Blood Marrow Transplant. sept, vol.23, issue.9, pp.1429-1465, 2017.
Acute lymphoblastic leukemia: a comprehensive review and 2017 update, Blood Cancer J. 30 juin, vol.7, issue.6, p.577, 2017. ,
Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation, Hematol Am Soc Hematol Educ Program. 8 déc, vol.2017, issue.1, pp.22-29, 2017. ,
Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia, Br J Haematol. déc, vol.179, issue.5, pp.705-728, 2017. ,
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity, Bone Marrow Transplant. avr, vol.51, issue.4, pp.479-91, 2016. ,
Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances, Hematol Oncol Stem Cell Ther. déc, vol.10, issue.4, pp.277-84, 2017. ,
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients, Biol Blood Marrow Transplant. sept, vol.22, issue.9, pp.1543-51, 2016. ,
Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?, J Oncol Pract. déc, vol.13, issue.12, pp.798-806, 2017. ,
Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant, 2014. ,
Role of allogeneic stem cell transplantation in mantle cell lymphoma, Eur J Haematol. avr, vol.94, issue.4, pp.290-297, 2015. ,
Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma, Blood Rev. mai, vol.29, issue.3, pp.143-52, 2015. ,
Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation, Crit Rev Oncol Hematol. févr, vol.89, issue.2, pp.248-61, 2014. ,
How I treat the peripheral T-cell lymphomas, Blood, vol.123, issue.17, pp.2636-2644, 2014. ,
Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis, Bone Marrow Transplant, vol.25, 2018. ,
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia, Ann Hematol. juill, vol.96, issue.7, pp.1185-96, 2017. ,
Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis, Bone Marrow Transplant. avr, vol.51, issue.4, pp.521-529, 2016. ,
Who is fit for allogeneic transplantation? Blood. 2 déc, vol.116, pp.4762-70, 2010. ,
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, vol.51, issue.10, pp.1283-300, 2016. ,
,
, Acta Haematol. oct, vol.20, issue.1-4, pp.156-66, 1958.
Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men, Hum Immunol. avr, vol.65, issue.4, pp.282-90, 2004. ,
Present Yourself! By MHC Class I and MHC Class II Molecules, Trends Immunol, vol.37, issue.11, pp.724-761, 2016. ,
On the future of HLA, Tissue Antigens, vol.78, issue.4, pp.229-269, 2011. ,
, Complete sequence and gene map of a human major histocompatibility complex, Nature, vol.401, pp.921-924, 1999.
, Marsh SGE, for the WHO Nomenclature Committee for Factors of the HLA System
, Nomenclature for factors of the HLA system, HLA. déc, vol.88, issue.6, pp.334-375, 2016.
The HLA system, N Engl J Med, vol.343, issue.10, pp.702-709, 2000. ,
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft, Blood. 11 mai, vol.129, issue.19, pp.2680-92, 2017. ,
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors, N Engl J Med, vol.367, issue.16, pp.1487-96, 2012. ,
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults ,
, Cochrane Database Syst Rev, vol.20
,
Transplantation of peripheral blood stem cells as compared with bone marrow from HLAidentical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 15 déc, vol.20, issue.24, pp.4655-64, 2002. ,
Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of Five Tests and Treatments to Question in Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 2018. ,
,
Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia, Blood. 15 août, vol.110, issue.4, pp.1397-400, 2007. ,
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category, Biol Blood Marrow Transplant, vol.16, issue.10, pp.1382-1389, 2010. ,
Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist, Blood, vol.124, issue.3, pp.334-343, 2014. ,
The National Marrow Donor Program 20 Years of Unrelated Donor Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant. sept, vol.14, issue.9, pp.2-7, 2008. ,
HLA Association with Hematopoietic Stem Cell Transplantation Outcome: The Number of Mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 Is Strongly Associated with Overall Survival ,
, Biol Blood Marrow Transplant. août, vol.13, issue.8, pp.965-74, 2007.
HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research, Biol Blood Marrow Transplant, vol.21, issue.10, pp.1783-1792, 2015. ,
High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism, Blood, vol.110, issue.7, pp.2235-2241, 2007. ,
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality, Blood, vol.21, issue.22, pp.3651-3659, 2013. ,
A closer look at permissive HLA mismatch, Blood, vol.122, issue.22, pp.3555-3556, 2013. ,
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation, Blood, vol.118, issue.25, pp.6691-6697, 2011. ,
Cord Blood Unit Access and Selection: 2010 and Beyond: Best Practices and Emerging Trends in Cord Blood Unit Selection, Biol Blood Marrow Transplant. janv, vol.17, issue.1, pp.46-51, 2011. ,
Improving outcomes in umbilical cord blood transplantation: State of the art, Blood Rev, vol.26, issue.6, pp.241-247, 2012. ,
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy, Blood. 28 sept, vol.105, issue.3, pp.1343-1350, 2004. ,
,
, Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood, Blood, vol.25, issue.22, pp.4693-4702, 2010.
Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts, Biol Blood Marrow Transplant. mai, vol.18, issue.5, pp.805-817, 2012. ,
Single-vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome, Blood. 30 juin, vol.127, issue.26, pp.3450-3457, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01482531
Haploidentical transplantation for hematologic malignancies: where do we stand?, vol.2012, pp.230-236, 2012. ,
Halfway there: the past, present and future of haploidentical transplantation, Bone Marrow Transplant, vol.52, issue.1, pp.1-6, 2017. ,
Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation, Blood, vol.128, issue.23, pp.2616-2623, 2016. ,
Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma, Bone Marrow Transplant, vol.12, 2018. ,
,
Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and antithymoglobulin for adult severe aplastic anaemia, Bone Marrow Transplant, vol.15, 2018. ,
,
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide, Biol Blood Marrow Transplant. juin, vol.14, issue.6, pp.641-50, 2008. ,
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT, J Hematol OncolJ Hematol Oncol ,
URL : https://hal.archives-ouvertes.fr/hal-01297485
,
, Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival
European experience of bone-marrow transplantation for severe combined immunodeficiency, The Lancet, vol.336, issue.8719, pp.850-854, 1990. ,
Are new conditioning regimens for transplants in acute myelogenous leukemia better?, Bone Marrow Transplant. avr, vol.7, issue.4, pp.255-61, 1991. ,
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy, Blood. 15 juin, vol.89, issue.12, pp.4531-4537, 1997. ,
,
Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum ,
, Biol Blood Marrow Transplant. mars, vol.15, issue.3, pp.367-376, 2009.
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation, Blood, vol.122, issue.24, pp.3871-3878, 2013. ,
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI, Blood, 2013. ,
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate-or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Biol Blood Marrow Transplant. févr, vol.23, issue.2, pp.278-84, 2017. ,
Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia, Haematologica. janv, vol.102, issue.1, pp.184-91, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01471574
Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT, Br J Haematol. févr ,
Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen, Biol Blood Marrow Transplant. mars, vol.18, issue.3, pp.466-72, 2012. ,
Intensive care management of patients following haematopoietic stem cell transplantation, Curr Anaesth Crit Care. avr, vol.19, issue.2, pp.80-90, 2008. ,
,
, Intravesical cidofovir application in BK virus cystitis after allogeneic hematopoetic stem cell transplantation (HSCT) is safe and highly effective, Bone Marrow Transplant, vol.12, 2018.
,
New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Transfus Apher Sci. avr, vol.54, issue.2, pp.181-90, 2016. ,
Endothelial cell damage in idiopathic pneumonia syndrome, Bone Marrow Transplant, vol.15, 2018. ,
,
, ALINEA Plus Ed, 2018.
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective, Biol Blood Marrow Transplant, vol.15, issue.10, pp.1143-238, 2009. ,
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective, Bone Marrow Transplant, vol.44, issue.8, pp.453-458, 2009. ,
How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation, Blood, vol.127, issue.22, pp.2682-2692, 2016. ,
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis, Blood. 19 mai, vol.127, issue.20, pp.2427-2465, 2016. ,
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016, 163. 159. on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation), vol.49, pp.1435-55, 2014. ,
,
, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med. 25 janv, vol.356, issue.4, pp.335-382, 2007.
How I vaccinate blood and marrow transplant recipients, Blood. 9 juin, vol.127, issue.23, pp.2824-2856, 2016. ,
Classification systems for chronic graft-versus-host disease, Blood, vol.129, issue.1, pp.30-37, 2017. ,
Graft-versus-host disease. The Lancet, vol.373, pp.1550-1561, 2009. ,
Acute Graft-versus-Host Disease -Biologic Process, Prevention, and Therapy. Longo DL, éditeur, N Engl J Med, vol.377, issue.22, pp.2167-79, 2017. ,
The danger model: a renewed sense of self, Science, vol.296, issue.5566, pp.301-305, 2002. ,
Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today? ,
, Curr Hematol Malig Rep, vol.26, 2018.
,
Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice, Sci Transl Med. 18 mai, vol.8, issue.339, pp.339-71, 2016. ,
Assessment of mucosal integrity by quantifying neutrophil granulocyte influx in murine models of acute intestinal injury, Cell Immunol. juin, vol.316, pp.70-76, 2017. ,
Monocyteinduced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease, J Immunol Baltim Md, vol.193, issue.7, pp.3355-65, 1950. ,
T-cell co-signalling molecules in graft-versus-host disease, Ann Hematol. juin, vol.79, issue.6, pp.283-90, 2000. ,
Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells downregulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM), Blood. 15 avr, vol.105, issue.8, pp.3372-80, 2005. ,
,
, Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality, J Clin Invest. 1 juill, vol.126, issue.7, pp.2642-60, 2016.
Leukocyte migration and graft-versus-host disease, Blood. 1 juin, vol.105, issue.11, pp.4191-4200, 2005. ,
Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation, J Clin Invest. 15 août, vol.100, issue.4, pp.904-915, 1997. ,
Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versustumor activity, Blood. 15 juill, vol.110, issue.2, pp.783-789, 2007. ,
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors, Transplantation. oct, vol.18, issue.4, pp.295-304, 1974. ,
Allogeneic transplantation of CD34+ selected hematopoietic cells--clinical problems and current challenges, Leuk Lymphoma. mars, vol.45, issue.3, pp.447-53, 2004. ,
Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (Tcell Depletion Trial): a multi-centre, randomised phase II-III trial, The Lancet, vol.366, issue.9487, pp.733-741, 2005. ,
Rabbit Anti-T Cell Globulin in Allogeneic Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant. juin, vol.21, issue.6, pp.959-70, 2015. ,
,
, Protective Conditioning for Acute Graft-versus-Host Disease, N Engl J Med. 29 sept, vol.353, issue.13, pp.1321-1352, 2005.
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol. sept, vol.10, issue.9, pp.855-64, 2009. ,
Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched ,
URL : https://hal.archives-ouvertes.fr/hal-01231422
, Transplantation. août, vol.100, issue.8, pp.1732-1741, 2016.
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial, Lancet Oncol, vol.17, issue.2, pp.164-173, 2016. ,
Acute graft-versus-host disease: a bench-tobedside update, Blood, vol.124, issue.3, pp.363-373, 2014. ,
Recent developments in HLA-haploidentical transplantations ,
, Best Pract Res Clin Haematol. juin, vol.28, issue.2-3, pp.141-147, 2015.
,
, Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLAmatched mobilized blood cell transplantation, Blood, vol.127, issue.11, pp.1502-1508, 2016.
Prophylaxis regimens for GVHD: systematic review and meta-analysis, Bone Marrow Transplant. avr, vol.43, issue.8, pp.643-53, 2009. ,
,
tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease, Haematologica. 19 janv, 2018. ,
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis, Blood, vol.129, issue.7, pp.906-916, 2017. ,
Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review, Biol Blood Marrow Transplant. juill, vol.18, issue.7, pp.982-990, 2012. ,
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes, Blood. 26 mars, vol.113, issue.13, pp.2888-94, 2009. ,
,
, Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versushost disease: a randomized controlled trial, Haematologica. 1 juin, vol.100, issue.6, pp.842-850, 2015.
First-and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation, Biol Blood Marrow Transplant. août, vol.18, issue.8, pp.1150-63, 2012. ,
How I treat refractory acute GVHD, Blood, vol.109, issue.10, pp.4119-4126, 2007. ,
28 as predictors of survival, Bone Marrow Transplant. 1 févr, 2018. ,
,
, Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis, Biol Blood Marrow Transplant. juill, vol.19, issue.7, pp.1129-1162, 2013.
A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD, Blood. 2 févr, vol.129, issue.5, pp.643-652, 2017. ,
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease, Blood. 15 mars, vol.109, issue.6, pp.2657-62, 2007. ,
28 as predictors of survival, Bone Marrow Transplant, issue.1, 2018. ,
,
,
, Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey, Leukemia. oct, vol.29, issue.10, pp.2062-2070, 2015.
Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials, Immunotherapy. avr, vol.10, issue.5, pp.391-402, 2018. ,
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease, Bone Marrow Transplant. août, vol.45, issue.8, pp.1347-51, 2010. ,
,
, Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis, Biol Blood Marrow Transplant. juill, vol.19, issue.7, pp.1129-1162, 2013.
,
, Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies, Biol Blood Marrow Transplant, vol.20, issue.11, pp.1677-86, 2014.
,
Extra corporeal photochemotherapy in steroid refractory graft versus host disease: A review of guidelines and recommendations, Transfus Apher Sci. juin, vol.56, issue.3, pp.376-84, 2017. ,
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse, Blood, vol.100, issue.2, pp.406-414, 2002. ,
,
, Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graftversus-host disease according to National Institutes of Health consensus criteria, Blood. 17 mars, vol.117, issue.11, pp.3214-3223, 2011.
Current issues in chronic graft-versus-host disease, Blood. 17 juill, vol.124, issue.3, pp.374-84, 2014. ,
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius, Blood. 9 juin, vol.117, issue.23, pp.6375-82, 2011. ,
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies, Blood. 5 janv, vol.129, issue.1, pp.13-21, 2017. ,
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, Biol Blood Marrow Transplant. févr, vol.23, issue.2, pp.211-245, 2017. ,
Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation, Blood. 18 juin, vol.113, issue.25, pp.6477-84, 2009. ,
Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T cells in acute GVHD, Blood. 23 avr, vol.125, issue.17, pp.2720-2723, 2015. ,
Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease, Sci Transl Med. 3 avr, vol.5, issue.179, pp.179-222, 2013. ,
Circulating T follicular helper cells with increased function during chronic graft-versus-host disease, Blood. 19 mai, vol.127, issue.20, pp.2489-97, 2016. ,
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease, Clin Cancer Res Off J Am Assoc Cancer Res, vol.13, issue.20, pp.6107-6121, 2007. ,
,
, Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease, Blood. 16 avr, vol.113, issue.16, pp.3865-74, 2009.
,
, Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versushost disease, Blood. 1 juill, vol.110, issue.1, pp.237-278, 2007.
,
, Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis, N Engl J Med. 22 juin, vol.354, issue.25, pp.2667-76, 2006.
Emerging therapeutics for controle of chronic GvHD, Biol Blood Marrow Transplant, vol.57, p.6, 2017. ,
Diagnosis and manifestations of chronic graft-versus-host disease, Best Pract Res Clin Haematol. juin, vol.21, issue.2, pp.251-258, 2008. ,
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report, Biol Blood Marrow Transplant. mars, vol.21, issue.3, pp.389-401, 2015. ,
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report, Biol Blood Marrow Transplant. juill, vol.21, issue.7, pp.1167-87, 2015. ,
How we treat chronic graft-versus-host disease, Blood. 22 janv, vol.125, issue.4, pp.606-621, 2015. ,
,
, Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study, Blood, vol.130, issue.20, pp.2186-2195, 2017.
,
Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center, Bone Marrow Transplant. avr, vol.53, issue.4, pp.503-509, 2018. ,
Mechanistic approaches for the prevention and treatment of chronic GVHD, Blood, vol.129, issue.1, pp.22-29, 2017. ,
Novel targets in the treatment of chronic graft-versushost disease, Leukemia. mars, vol.31, issue.3, pp.543-54, 2017. ,
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease, Bone Marrow Transplant ,
,
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy, Blood, vol.129, issue.15, pp.2186-2197, 2017. ,
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy, Blood, vol.130, issue.21, pp.2243-2250, 2017. ,
One million haemopoietic stem-cell transplants: a retrospective observational study, Lancet Haematol. mars, vol.2, issue.3, pp.91-100, 2015. ,
Second Malignancies after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, vol.13, pp.1121-1155, 2007. ,
,
, Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfancyclophosphamide conditioning, Blood, vol.117, issue.1, pp.316-322, 2011.
Solid cancers after allogeneic hematopoietic cell transplantation, Blood, vol.113, issue.5, pp.1175-1183, 2009. ,
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report, Biol Blood Marrow Transplant. mars, vol.23, issue.3, pp.367-78, 2017. ,
How I treat late effects in adults after allogeneic stem cell transplantation, Blood, vol.117, issue.11, pp.3002-3009, 2011. ,
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study, Blood. 15 mai, vol.105, issue.10, pp.3802-3813, 2005. ,
Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation, J Clin Oncol Off J Am Soc Clin Oncol. 1 mars, vol.24, issue.7, pp.1119-1145, 2006. ,
,
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report, Biol Blood Marrow Transplant. juin, vol.23, issue.6, pp.870-81, 2017. ,
,
, Clin Oncol Off J Am Soc Clin Oncol. 20 févr, vol.28, issue.6, pp.1011-1017, 2010.
Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation, Bone Marrow Transplant. mai, vol.41, issue.9, pp.797-804, 2008. ,
High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, vol.43, issue.1, pp.49-54, 2009. ,
Endocrinological late complications after hematopoietic SCT in children, Bone Marrow Transplant. juin, vol.41, pp.43-51, 2008. ,
Thyroid function following hematopoietic cell transplantation in children: 30 years9 experience, Blood, vol.113, issue.2, pp.306-308, 2009. ,
Prolonged Chronic Graft-versus-Host Disease is a Risk Factor for Thyroid Failure in Long-Term Survivors After Matched Sibling Donor Stem Cell Transplantation for Hematologic Malignancies, Biol Blood Marrow Transplant. mars, vol.15, issue.3, pp.377-81, 2009. ,
Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment, Semin Hematol. janv, vol.49, issue.1, pp.15-24, 2012. ,
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation, Jama, vol.302, issue.3, pp.306-314, 2009. ,
Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant. juill, vol.13, issue.7, pp.749-59, 2007. ,
Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation, Bone Marrow Transplant, vol.30, 2018. ,
,
Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a one-year follow-up pilot study, J Clin Exp Neuropsychol. avr, vol.28, issue.3, pp.283-93, 2006. ,
Prospective evaluation of neurological complications after allogeneic bone marrow transplantation, Neurology, vol.60, issue.5, pp.842-848, 2003. ,
,
, Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT, Bone Marrow Transplant, vol.17, 2018.
,
Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation, Cancer. 1 juill, vol.118, issue.13, pp.3407-3423, 2012. ,
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes, Biol Blood Marrow Transplant. janv, vol.23, issue.1, pp.6-9, 2017. ,
,
,
Elévation des transaminases, p.17, 2018. ,
,
Hepatobiliary Complications of Hematopoietic Cell Transplantation, p.40 ,
, Years On. Hepatology. avr, vol.51, issue.4, pp.1450-60, 2010.
Longterm liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients, Bone Marrow Transplant, vol.26, issue.6, p.649, 2000. ,
Liver disease after hematopoietic cell transplantation in adults, Transplant Rev. janv, vol.29, issue.1, pp.8-15, 2015. ,
How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver, Blood, vol.127, issue.12, pp.1544-1550, 2016. ,
Hepatic graftversus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid, Liver, vol.22, issue.6, pp.514-517, 2002. ,
Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis, Am J Gastroenterol, vol.96, issue.2, pp.588-590, 2001. ,
Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis, Hepatology. déc, vol.32, issue.6, pp.1265-71, 2000. ,
Cirrhosis as a consequence of graft-versus-host disease, Gastroenterology. févr, vol.92, issue.2, pp.513-522, 1987. ,
,
, Cirrhosis of the liver in long-term marrow transplant survivors, Blood, vol.93, issue.10, pp.3259-3266, 1999.
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, Biol Blood Marrow Transplant. févr, vol.23, issue.2, pp.211-245, 2017. ,
Histologie du foie ,
Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and Liver: An Update, Am J Clin Pathol. mai, vol.145, issue.5, pp.591-603, 2016. ,
,
, Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II, Pathology Working Group Report. Biol Blood Marrow Transplant. janv, vol.12, issue.1, pp.31-47, 2006.
A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation, Hepatol Baltim Md. juin, vol.8, issue.3, pp.463-70, 1988. ,
Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD), J Gastrointest Oncol, vol.7, issue.1, p.21, 2016. ,
Review article: management of hepatic disease following haematopoietic cell transplant, Aliment Pharmacol Ther. août, vol.24, issue.3, pp.441-52, 2006. ,
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation, Blood. 28 août, vol.100, issue.6, pp.1977-83, 2002. ,
Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT), Bone Marrow Transplant. juin, vol.50, issue.6, pp.781-790, 2015. ,
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation ,
, Bone Marrow Transplant, pp.31-2017
,
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation, Bone Marrow Transplant. juill, vol.51, issue.7, pp.906-918, 2016. ,
Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes, Bone Marrow Transplant, vol.51, issue.3, p.403, 2016. ,
Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease), J Clin Exp Hepatol. déc, vol.4, issue.4, pp.332-378, 2014. ,
Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense, J Pharmacol Exp Ther. mars, vol.268, issue.3, pp.1261-70, 1994. ,
Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation, Hepatology, vol.24, issue.4, pp.830-837 ,
Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease, Hepatology, vol.23, issue.3, pp.589-99 ,
Characterization of a reproducible rat model of hepatic veno-occlusive disease, Hepatology, vol.29, issue.6, pp.1779-91 ,
Syndrome d'obstruction sinusoïdale (maladie veino-occlusive). Réanimation, vol.16, pp.626-657, 2007. ,
Using liver ,
,
Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients, Transplantation. 15 avr, vol.59, issue.7, pp.1015-1037, 1995. ,
Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors, Hepatology, vol.4, issue.1, pp.116-122, 1984. ,
,
, Venoocclusive disease of the liver following bone marrow transplantation, Transplantation. déc, vol.44, issue.6, pp.778-83, 1987.
BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation, Br J Haematol, vol.163, issue.4, pp.444-57, 2013. ,
On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease, Ann Hematol. févr, vol.66, issue.2, pp.77-80, 1993. ,
Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial, Ann Intern Med. 15 juin, vol.128, issue.12, pp.975-81, 1998. ,
Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial, Blood. 1 juin, vol.79, issue.11, pp.2834-2874, 1992. ,
Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients, J Pediatr Hematol Oncol. déc, vol.24, issue.9, pp.746-50, 2002. ,
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. juill, vol.16, issue.7, pp.1005-1022, 2010. ,
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multiorgan failure, Blood. 31 mars, vol.127, issue.13, pp.1656-65, 2016. ,
What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance, Blood. 31 mars, vol.127, issue.13, pp.1719-1746, 2016. ,
Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation, Blood, vol.122, issue.6, pp.1079-1086, 2013. ,
The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?, Ann Hematol. mai, vol.92, issue.5, pp.577-86, 2013. ,
Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies, Crit Rev Oncol Hematol. mai, vol.113, pp.156-70, 2017. ,
Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major: Transplantation and iron overload, Ann N Y Acad Sci. mars, vol.1368, issue.1, pp.115-136, 2016. ,
Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation ,
, Biol Blood Marrow Transplant. juin, vol.17, issue.6, pp.852-60, 2011.
Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. mai, vol.12, issue.5, pp.506-516, 2006. ,
,
, Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations, Hepatol Baltim Md. févr, vol.59, issue.2, pp.661-70, 2014.
,
, Hepatology. mars, vol.49, issue.3, pp.1017-1061, 2009.
Transjugular liver biopsy: Indications, technique and results, Diagn Interv Imaging. janv, vol.95, issue.1, pp.11-16, 2014. ,
Chronic Liver Disease: Noninvasive Subharmonic Aided Pressure Estimation of Hepatic Venous Pressure Gradient, Radiology. août, vol.268, issue.2, pp.581-589, 2013. ,
,
, Transjugular liver biopsy: how good is it for accurate histological interpretation?, Gut. 1 déc, vol.55, issue.12, pp.1789-94, 2006.
Transjugular liver biopsy using ultrasonographic guidance for jugular vein puncture and an automated device for hepatic tissue sampling: a retrospective analysis of 200 consecutive cases, Abdom Imaging. déc, vol.33, issue.6, pp.627-659, 2008. ,
Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation, J Pediatr Hematol Oncol. avr, vol.33, issue.3, pp.92-97, 2011. ,
Liver biopsy, N Engl J Med. 15 févr, vol.344, issue.7, pp.495-500, 2001. ,
,
Utility of liver biopsy in bone marrow transplant patients, J Gastroenterol Hepatol. févr, vol.23, issue.2, pp.222-227, 2008. ,
Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study, Bone Marrow Transplant, vol.26, issue.2, p.193, 2000. ,
Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy, Eur J Gastroenterol Hepatol. févr, vol.16, issue.2, pp.157-62, 2004. ,
The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant, vol.42, pp.461-468, 2008. ,
Iron overload in allogeneic hematopoietic stem cell transplant recipients, Arch Pathol Lab Med. mai, vol.136, issue.5, pp.532-540, 2012. ,
Safety and utility of percutaneous liver biopsy in hematopoietic stem cell transplant pediatric recipients: a retrospective study, BMC Cancer, p.2, 2016. ,
, , pp.30426-30435
, Biology of Blood and Marrow Transplantation Received date, 2018.
, Utility and safety of liver biopsy in patients with undetermined liver blood test anomalies after allogeneic hematopoietic stem cell transplantation, a monocentric retrospective cohort study, Biology of Blood and Marrow Transplantation, 2018.
As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. References 1, This is a PDF file of an unedited manuscript that has been accepted for publication, vol.363, pp.2091-2101, 2010. ,
Advances in prevention and treatment of hepatic disorders following hematopoietic cell transplantation, Best Pract Res Clin Haematol, vol.19, issue.2, pp.341-352, 2006. ,
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients, Blood, vol.103, issue.1, pp.78-84, 2004. ,
Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome, Bone Marrow Transplant, vol.44, issue.7, pp.441-447, 2009. ,
Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation, Hepatology, vol.41, issue.2, pp.345-352, 2005. ,
Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant, vol.18, issue.10, pp.1589-1599, 2012. ,
Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation, Eur J Gastroenterol Hepatol, vol.16, issue.12, pp.1347-1354, 2004. ,
Hepatobiliary Complications of Hematopoietic Cell Transplantation, 40 Years On, Hepatology, vol.51, issue.4, pp.1450-1460, 2010. ,
Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients, Bone Marrow Transplant, vol.26, issue.6, pp.649-655, 2000. ,
Liver disease after hematopoietic cell transplantation in adults, Transplant Rev, vol.29, issue.1, pp.8-15, 2015. ,
How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver, Blood, vol.127, issue.12, pp.1544-1550, 2016. ,
,
Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid, Liver, vol.22, issue.6, pp.514-517, 2002. ,
Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis, Am J Gastroenterol, vol.96, issue.2, pp.588-590, 2001. ,
Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis, Hepatology, vol.32, issue.6, pp.1265-1271, 2000. ,
Cirrhosis as a consequence of graft-versus-host disease, Gastroenterology, vol.92, issue.2, pp.513-519, 1987. ,
Cirrhosis of the liver in long-term marrow transplant survivors, Blood, vol.93, issue.10, pp.3259-3266, 1999. ,
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation, Bone Marrow Transplant, vol.51, issue.7, pp.906-912, 2016. ,
Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes, Bone Marrow Transplant, vol.51, issue.3, pp.403-409, 2016. ,
Syndrome d'obstruction sinusoïdale (maladie veino-occlusive), Réanimation, vol.16, issue.7-8, pp.626-631, 2007. ,
Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors, Hepatology, vol.4, issue.1, pp.116-122, 1984. ,
Venoocclusive disease of the liver following bone marrow transplantation, Transplantation, vol.44, issue.6, pp.778-783, 1987. ,
Cholestasis after hematopoietic cell transplantation, Clin Liver Dis, vol.3, issue.3, pp.651-668, 1999. ,
Chronic cholestasis in patients after allogeneic bone marrow transplantation: several diseases are often associated, Bone Marrow Transplant, vol.16, issue.2, pp.261-265, 1995. ,
Imaging Evaluation of Pulmonary and Abdominal Complications Following Hematopoietic Stem Cell Transplantation1, RadioGraphics, vol.25, issue.2, pp.305-317, 2005. ,
,
Transjugular liver biopsy in BMT, Bone Marrow Transplant, vol.11, issue.1, pp.21-26, 1993. ,
Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients, Transplantation, vol.59, issue.7, pp.1015-1022, 1995. ,
Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review, J Hepatol, vol.47, issue.2, pp.284-294, 2007. ,
Transjugular liver biopsy: how good is it for accurate histological interpretation?, Gut, vol.55, issue.12, pp.1789-1794, 2006. ,
Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation, Radiology, vol.258, issue.3, pp.660-671, 2011. ,
Assessing the Risk of Hemorrhagic Complication following Transjugular Liver Biopsy in Bone Marrow Transplantation Recipients, J Vasc Interv Radiol JVIR, vol.27, issue.4, pp.551-557, 2016. ,
Liver biopsy, N Engl J Med, vol.344, issue.7, pp.495-500, 2001. ,
Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and Liver: An Update, Am J Clin Pathol, vol.145, issue.5, pp.591-603, 2016. ,
Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation, Virchows Arch, vol.464, issue.2, pp.175-190, 2014. ,
A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation, Hepatol Baltim Md, vol.8, issue.3, pp.463-470, 1988. ,
Histological and ultrastructural appearance of the liver during graft-versus-host disease complicating bone marrow transplantation, Transplantation, vol.29, issue.3, pp.236-244, 1980. ,
Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD), vol.7, p.11, 2016. ,
Circos: an information aesthetic for comparative genomics, Genome Res, vol.19, issue.9, pp.1639-1645, 2009. ,
,
, le nouveau chapitre IX est applicable | CNIL, 2018.
Utility of liver biopsy in bone marrow transplant patients, J Gastroenterol Hepatol, vol.23, issue.2, pp.222-225, 2008. ,
Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis, Hepatol Baltim Md, vol.4, issue.1, pp.123-130, 1984. ,
Diagnostic yield of transjugular liver biopsy samples to evaluate for infectious etiology of liver dysfunction in bone marrow transplant recipients, Cardiovasc Intervent Radiol, vol.37, issue.2, pp.471-475, 2014. ,
Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study, Bone Marrow Transplant, vol.26, issue.2, pp.193-197, 2000. ,
Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy, p.6 ,
The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated?, Bone Marrow Transplant, vol.42, issue.7, pp.461-467, 2008. ,
Iron overload in allogeneic hematopoietic stem cell transplant recipients, Arch Pathol Lab Med, vol.136, issue.5, pp.532-538, 2012. ,
Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation, J Pediatr Hematol Oncol, vol.33, issue.3, pp.92-97, 2011. ,
Transjugular liver biopsy: Indications, technique and results, Diagn Interv Imaging, vol.95, issue.1, pp.11-15, 2014. ,
Safety and utility of percutaneous liver biopsy in hematopoietic stem cell transplant pediatric recipients: a retrospective study, BMC Cancer, vol.16, p.590, 2016. ,
, 75006 Paris Résumé Les anomalies du bilan hépatique sont fréquentes après une allogreffe de cellules souches hématopoïétiques (CSH) mais leur étiologie reste parfois difficile à identifier. Notre objectif était d'évaluer la sécurité et l'utilité des ponctions biopsies hépatiques (PBH) chez des patients allogreffés, cette étude rétrospective mono-centrique, nous avons identifié 54 biopsies réalisées chez 45 patients entre juin 2005 et juillet 2017 après une allogreffe de CSH. Le délai médian entre l'allogreffe et la PBH était de 213 jours
, En conclusion, la réalisation d'une PBH pour explorer des anomalies du bilan hépatique post-allogreffe de CSH est une procédure sûre dont les résultats ont un impact significatif sur la prise en charge des patients allogreffés. Mots clefs : Allogreffe de cellules souches hématopoïétiques, ponction biopsie hépatique, complications hépatiques post-allogreffe Abstract Liver blood tests abnormalities are common after allogeneic hematopoietic stem cell transplantation (allo-HSCT) but their cause often remains difficult to identify. Our objective was to evaluate the safety and utility of liver biopsy in patients who underwent allo-HSCT. In a retrospective single center cohort study, we reviewed all cases of patients who underwent liver biopsy between, 5% des biopsies (51/54) ont permis d'obtenir un diagnostic histologique. Trente pourcents des biopsies ont permis le diagnostic de maladie du greffon contre l'hôte cholestéatique, 17% celui d'hépatite allo-immune, 5% celui de syndrome d'obstruction sinusoïdale. Les données cliniques (hépatomégalie, hypertension portale, prise de poids), vol.94, 2005.